Abstract
The microbiome plays a fundamental role in how the immune system develops and how inflammatory responses are shaped and regulated. The "gut-lung axis" highlights a crucial biological crosstalk between the intestinal microbiome and lung. A growing body of literature suggests that dysbiosis—the perturbation of the gut microbiome—is a driving force behind the development and severity of allergic asthma. Animal models have provided insights into how gut microbe-derived components and metabolites, such as short-chain fatty acids (SCFAs), influence asthma development. While the full understanding of how SCFAs influence allergic airway disease remains obscure, a recurring theme of epigenetic regulation of gene expression in several immune cell compartments is emerging. This review addresses our current understanding of how SCFAs, specifically butyrate, orchestrate cell behavior and epigenetic changes, providing a detailed overview of these modifications on immune cells in the context of allergic airway disease.
Introduction: The Gut-Lung Axis
Allergic asthma is a complex inflammatory disease characterized by an overactive immune response to environmental allergens. While the influence of the gut microbiome on systemic immunity has been recognized, the precise molecular mechanisms connecting intestinal metabolites to lung inflammation have remained elusive. This review focuses on butyrate, a four-carbon SCFA produced by gut bacteria, as a primary mediator of this "gut-lung axis." It addresses the gap between clinical observations—such as the "window of opportunity" in early childhood where microbial diversity prevents asthma—and the specific cellular mechanisms butyrate employs to orchestrate immune tolerance.
Mechanisms of Action: Epigenetics and Sensing
Butyrate influences immune cells through two primary pathways: signaling via G protein-coupled receptors (GPR41, GPR43, GPR109A) and direct inhibition of Histone Deacetylases (HDACs).
The most profound effects in asthma appear to stem from HDAC inhibition. By entering the cell and preventing the removal of acetyl groups from histones, butyrate maintains an "open" chromatin state. This promotes the expression of anti-inflammatory genes, such as Foxp3, while suppressing pro-inflammatory pathways. This epigenetic "programming" is particularly critical during a "window of opportunity" in early life (pre-natal to weaning), where microbial diversity can permanently shape the immune trajectory.
Multi-Pronged Immune Modulation
Butyrate targets the entire allergic cascade across multiple cell lineages:
- Regulatory T cells (Tregs): Butyrate (at 100–125 µM) promotes the differentiation of naïve T cells into FoxP3+ Tregs, essential for suppressing airway hyperresponsiveness.
- Eosinophils: In vitro studies show that butyrate (3–10 mM) induces the intrinsic apoptotic pathway in human eosinophils.
- Dendritic Cells: It inhibits the migration of these cells to the lungs, preventing allergen presentation.
- B cells: High-fiber diets (increasing butyrate) correlate with decreased IgE production and reduced expression of Aicda, the gene essential for antibody class switching.
Clinical Evidence and the Concentration Paradox
Landmark longitudinal studies support these mechanistic findings. The PASTURE Study showed that children with high fecal butyrate levels at age one were significantly less likely to develop asthma by age six. Similarly, the CHILD Study identified specific butyrate-producing bacterial signatures in infancy that protect against atopy.
However, a significant challenge remains: the "concentration gap." While in vitro effects often require millimolar (mM) concentrations, systemic levels in human peripheral blood are typically in the micromolar (µM) range.
As shown in Figure 3, systemic butyrate concentrations across multiple human studies consistently fall within the 1–30 µM range. Researchers hypothesize that repeated, low-level exposure of immune precursors (HSPCs) in the bone marrow or blood may be sufficient to shift developmental fates, despite the lower absolute concentration compared to the colon.
Future Directions
Supplementing butyrate in adults has shown limited success, suggesting that therapeutic timing is paramount. Future research must focus on the perinatal period or the development of more potent, isoform-specific HDAC inhibitors. Additionally, optimizing the gut microbiota to produce butyrate naturally remains the most practical path forward for asthma prevention.
Summary updated